Charlie J Nicholls (Charlie Nicholls)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 6

Top Topics

Systemic Lupus Erythematosus

Skeletal Muscle

Glycemic Control

Top Venues

Diabetes, obesity & metabolism

Endocrinology, diabetes & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

William H Polonsky, Francesco Giorgino, Julio Rosenstock, Katherine Whitmire, Elisheva Lew, Mathieu Coudert, Agustina Alvarez, Charlie J Nicholls, Rory J McCrimmon
Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial. Diabetes, obesity & metabolism 24 (12) (2022)
Timothy S Bailey, Jasvinder Gill, Merwyn Jones S, Laxmi Shenoy, Charlie J Nicholls, Jukka Westerbacka
Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study. Diabetes, obesity & metabolism 24 (8) (2022)
Sean D Sullivan, Nick Freemantle, Rishab A Gupta, Jasmanda Wu, Charlie J Nicholls, Jukka Westerbacka, Timothy S Bailey
Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study. Endocrinology, diabetes & metabolism (2021)
Esmeralda Castelblanco, Jukka Westerbacka, Charlie J Nicholls, Jasmanda Wu, Rishab Gupta, Björn Eliasson
How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting? Diabetes, obesity & metabolism 23 (3) (2020)
Fang Liz Zhou, Charlie J Nicholls, Lin Xie, Yuexi Wang, Neel Vaidya, Stephen H Mandy
Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting. Endocrinology, diabetes & metabolism 2 (3) (2019)
Sean D Sullivan, Charlie J Nicholls, Rishab A Gupta, Arjun A Menon, Jasmanda Wu, Jukka Westerbacka, Zsolt Bosnyak, Juan Pablo Frias, Timothy S Bailey
Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study. Diabetes, obesity & metabolism 21 (9) (2019)